Target trial emulations: bridging the gap between clinical trial and real‐world data

This article refers to ‘Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care’ by M. Trevisan et al., published in this issue on pages 1698–1707. Clinical guidelines have designated mineralocorticoid receptor antagonists (MRAs) as a class I indicated treatment for patients with heart failure with reduced ejection fraction in the absence of contraindications.1, 2 Despite this, MRAs have...